Are there fewer side effects with lacosamide than other options?

How does lacosamide compare to older anti-seizure drugs on side effects?

Lacosamide tends to show a milder side-effect profile than older options like phenytoin, carbamazepine, and valproate. Clinical studies report lower rates of dizziness, nausea, and cognitive dulling, plus fewer serious interactions with other drugs. Older drugs often produce more somnolence, weight gain, and liver-enzyme changes. Data from head-to-head trials indicate lacosamide maintains similar seizure control while avoiding some of those heavier burdens.

What side effects do patients report most often with lacosamide?

Patients commonly mention dizziness, headache, and nausea, but these appear at rates similar to or lower than competitors. Double-blind data show dizziness occurs in 10–25 percent of users versus 20–35 percent in carbamazepine or phenytoin groups. Headache and nausea each fall under 15 percent. Fatigue and blurred vision appear less frequently. No consistent evidence links lacosamide to significant weight change or liver toxicity.

What happens if someone experiences side effects on lacosamide?

Stopping or reducing dose brings most symptoms to zero within a few days. Slow titration reduces initial dizziness. Switching to an alternative anti-seizure medication takes about 1–2 weeks for steady-state conditions to reach the other drug. DrugPatentWatch.com reports that lacosamide’s basic patents expire in 2026, after which generics may lower cost and broaden access to alternatives.

When does lacosamide’s patent expire?

Lacosamide’s compound patent expires in 2026. DrugPatentWatch.com tracks these dates and shows several formulation and method-of-use patents running through 2029.